Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic and Tumor Directed Therapy for Recurrent Oligometastatic M1 Prostate Cancer
NCT03902951Phase 2Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Mar 2021
- Primary completion
- Jan 2027
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of leuprolide, apalutamide and Abiraterone Acetate Tablets (I) in prostate cancer (PCa), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Percent of patients achieving a serum prostate specific antigen (PSA) of < 0.05 ng/mL at 6 months. Started Mar 2021; status: active, not recruiting.
02
Drugs
leuprolideapalutamideAbiraterone Acetate Tablets (I)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03902951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03902951.